ImmunityBio Q3 revenue rises on Anktiva sales growth but misses estimates
IBRX•ImmunityBio's third-quarter revenue rose 53% year over year to $48.84 million, below the $59.25 million analyst consensus. The company reported a net loss of $184.57 million.
1. Revenue and loss
ImmunityBio said third-quarter revenue increased 53% year over year to $48.84 million, driven by higher ANKTIVA sales and adoption among U.S. urologists and expanded market access. Revenue missed the $59.25 million consensus estimate. The company reported a net loss of $184.57 million and a loss per share of $0.18.
2. ANKTIVA expansion
The company cited FDA approval for expanded use of ANKTIVA with BCG in BCG-unresponsive non-muscle invasive bladder cancer, new approvals in Israel and first commercial doses in Europe. It expects to submit a supplemental biologics license application to the FDA for ANKTIVA in BCG-naïve non-muscle invasive bladder cancer in the fourth quarter of 2026.
